Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells

Fig. 2

UM171a-treated MSCs cross-present soluble antigens. A Schematic diagram showing the design of the antigen cross-/presentation assay. B UM171a triggers de novo cross-presentation by MSCs and enhances antigen presentation. C Schematic diagram showing the design of the antigen cross-presentation assay in response to 3- or 7-day treatment. D OVA cross-presentation response following a 3- or 7-day treatment. E Antigen presentation assay conducted on primary MEFs treated with UM171a. F Assessment of EPCR expression by flow-cytometry on the surface of UM171a-treated MEFs. The dashed line represents the DMSO signal. G Flow-cytometry assessment of fluorescent OVA uptake by UM171a-treated MSCs. DMSO-treated cells are shown by gray histograms, whereas UM171a-treated cells are depicted in red. H Evaluating OVA processing as in panel G. All experiments were repeated at least three times. For panels B, D and E, n = 6/group with *P < 0.05 and ***P < 0.001

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512